Table 7 Association of miR-10b and miR-21 and clinicopathological features in breast cancer patients

Age groups

< 45 years (n= 18)

42.24 (15.97–116.73)

22.96 (9.81–47.31)

> 45 years (n= 52)

27.70 (11.33–56.38)

15.45 (6.75–24.34)

Pvalue

0.313

0.162

Menopausal state

Pre (n= 25)

32.60 (14.49–78.63)

27.36 (15.71–37.90)

Post (n= 45)

27.80 (11.37–57.96)

13.87 (4.27–21.02)

Pvalue

0.650

0.008

Family history

Negative (n= 61)

30.63 (13.90–78.63)

18.05 (8.48–30.57)

Positive (n= 9)

24.54 (11.29–51.88)

14.87 (4.27–17.08)

Pvalue

0.636

0.094

Oral contraceptive pills

Negative (n= 43)

27.61 (10.76–53.71)

17.2 (4.36–35.36)

Positive (n= 27)

34.23 (15.97–116.73)

15.93 (7.33–27.55)

Pvalue

0.252

0.819

Tumor size

< 2 cm (n= 44)

29.22 (13.90–78.63)

19.75 (5.69–37.25)

> 2 cm (n= 26)

29.12 (12.18–70.38)

15.56 (7.33–18.56)

Pvalue

0.927

0.079

Breast cancer pathology

Duct (n= 63)

27.61 (12.18–70.38)

16.84 (6.47–27.74)

Lobular (n= 7)

32.60 (6.48–178.16)

21.02 (15.18–78.47)

Pvalue

0.660

0.207

Breast cancer subtype

Luminal A (n= 30)

38.53 (19.39–78.63)

17.68 (8.48–29.73)

Luminal B (n= 19)

24.54 (11.37–78.63)

18.82 (12.76–42.05)

Enriched (n= 11)

30.63 (10.76–70.38)

15.18 (2.63–32.76)

Basal (n= 5)

14.49 (13.90–51.88)

7.33 (6.47–19.89)

Pvalue

0.761

0.29

Breast cancer stage

1 (n= 2)

32.49 (8.21–56.77)

20.34 (2.78–37.90)

2A (n= 10)

21.07 (6.62–55.99)

14.24 (9.81–19.89)

2B (n= 22)

27.42 (13.90–78.63)

25.34 (14.87–47.31)

3A (n= 5)

46.75 (37.19–158.35)

17.2 (4.36–18.05)

3B (n= 2)

112.12 (30.63–193.61)

18.1 (15.18–21.02)

4 (n= 29)

27.61 (10.76–57.96)

12.76 (7.03–25.33)

Pvalue

0.674

0.435

Breast cancer grade

Grade 1 (n= 4)

100.34 (52.20–169.51)

13.10 (7.06–25.24)

Grade 2 (n= 58)

25.90 (11.29–73.36)

18.30 (8.48–29.73)

Grade 3 (n= 8)

29.38 (18.52–63.57)

9.90 (4.31–17.20)

Pvalue

0.128

0.305

Lymph node

Negative (n= 14)

21.22 (8.21–56.77)

14.24 (3.98–21.02)

Positive (n= 56)

30.63 (13.04–78.63)

17.14 (7.18–29.73)

Pvalue

0.618

0.725

T

T1 (n= 6)

57.36 (46.43–142.72)

13.10 (2.78–36.61)

T2 (n= 39)

24.20 (12.18–70.38)

21.47 (9.81–47.31)

T3 (n= 12)

40.26 (14.47–155.66)

13.22 (6.12–18.30)

T4 (n= 13)

24.54 (9.83–34.23)

12.76 (7.03–17.32)

Pvalue

0.315

0.153

N

N0 (n= 14)

21.22 (8.21–56.77)

14.24 (3.98–21.02)

N1 (n= 49)

30.63 (13.90–78.63)

17.32 (7.03–29.73)

N2 (n= 5)

21.07 (11.29–46.75)

16.84 (11.27–19.62)

N3 (n= 2)

23.17 (5.93–40.42)

10.62 (8.48–12.76)

Pvalue

0.735

0.791

M

M0 (n= 41)

31.62 (13.04–76.0)

18.56 (7.08–32.55)

M1 (n= 29)

26.07 (10.76–57.96)

13.32 (7.03–27.36)

Pvalue

0.529

0.198

Estrogen receptor (ER)

Negative (n= 17)

30.63 (13.90–51.88)

7.33 (2.63–19.89)

Positive (n= 53)

27.80 (12.18–78.63)

18.05 (10.51–29.73)

Pvalue

0.758

0.066

Progesterone receptor (PR)

Negative (n= 21)

14.49 (9.56–46.75)

7.33 (2.636–19.89)

Positive (n=49)

35.43 (15.97–78.63)

18.05 (11.27–29.73)

Pvalue

0.102

0.032

HER2

Negative (n= 44)

27.70 (11.01–68.30)

17.26 (7.18–27.46)

Positive (n= 26)

30.63 (14.49–73.36)

15.45 (4.36–32.76)

Pvalue

0.794

0.841

Combined ER/PR

ER−/PR−

27.00 (12.33–61.33)

11.25 (2.72–26.33)

ER+/PR−

9.56 (8.21–9.83)

2.78 (2.35–18.56)

ER−/PR+

35.43 (35.43–35.43)

1.45 (1.45–1.45)

ER+/PR+

35.71 (15.97–78.63)

18.30 (11.80–30.15)

Pvalue

0.122

0.034

Metastatic work up

Free (n= 40)

31.62 (13.04–76.00)

18.56 (7.08–32.55)

Bone (n= 10)

52.20 (27.80–142.72)

13.32 (11.27–30.57)

Liver (n= 6)

31.35 (9.30–78.63)

9.90 (7.33–18.82)

Bone, liver (n= 5)

24.54 (15.97–34.23)

15.93 (7.03–17.08)

Bone, lung (n= 6)

10.29 (6.95–14.49)

21.10 (2.35–32.76)

Liver, lung (n= 1)

35.43 (35.43–35.43)

1.45 (1.45–1.45)

Bone, lung, liver (n= 2)

19.05 (13.90–24.20)

16.92 (6.47–27.36)

Pvalue

0.194

0.583